MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Dec 18, 11:57 AM (EDT)
Price
$30.19
Change
-$0.14 (-0.46%)
Net Assets
13.65M

HELX stock forecast, quote, news & analysis

Category: @Health
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for HELX with price predictions
Dec 17, 2024

HELX sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for HELX moved below the 200-day moving average on November 11, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on HELX as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HELX turned negative on December 17, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

HELX moved below its 50-day moving average on December 10, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HELX entered a downward trend on November 25, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HELX's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

HELX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 40.62B. The market cap for tickers in the group ranges from 299.56M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is FDMT at 299.56M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 9%. For the same ETF, the average monthly price growth was 27%, and the average quarterly price growth was 96%. NBIX experienced the highest price growth at 6%, while PACB experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was -47% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 67
Price Growth Rating: 52
SMR Rating: 78
Profit Risk Rating: 67
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com